Muscle Relaxant Drugs Market Trends

  • Report ID: 486
  • Published Date: Oct 10, 2024
  • Report Format: PDF, PPT

Muscle Relaxant Drugs Market Trends

Growth Drivers

  • Increasing Sedentary Lifestyle and Decreasing Activity Levels – is a crucial reason amongst all other reasons responsible for increasing muscle weakness and musculoskeletal diseases, and is expected to drive the demand for muscle relaxant drugs in the projected period. For instance, global estimates show 81% of adolescents and 1 in 4 adults do not indulge in enough physical activity. Levels of inactivity in economically developed countries are as high as 70%.
  • Rising Number of Patients with Lower Back Pain - according to the World Health Organization, 570 million people are suffering from low back pain worldwide, contributing to 7.4% of years lived with disability (YLDs) across the globe.
  • Upsurge in the Number of People Suffering from Osteoarthritis (OA) – it was found that there were 527.81 million prevalent cases of OA globally in 2019.
  • Growing Geriatric Population - according to the World Health Organization in 2019, there are 1 billion people aged 60 years and older. The number is expected to increase to 1.4 billion by 2030 and 2.1 billion by 2050.
  • Rising Number of Cases Related to Fibromyalgia – as per estimates, fibromyalgia affects approximately 4 million US adults, about 2% of the total adult population.

Challenges

  • Restrictions on the Use of Muscle Relaxants – which are mostly restricted for pregnant women and alcohol-addicted people. Muscle relaxants when combined with alcohol, may result in confusion, drowsiness, and errors in judgment.
  • Side effects Associated with Liver Dysfunctional Problems and Respiratory Organs
  • Short-term Relief Provider

Muscle Relaxant Drugs Market: Key Insights

Base Year

2024

Forecast Year

2025-2037

CAGR

6.9%

Base Year Market Size (2024)

USD 3.43 million

Forecast Year Market Size (2037)

USD 8.06 million

Regional Scope

  • North America (U.S., and Canada)
  • Latin America (Mexico, Argentina, Rest of Latin America)
  • Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific)
  • Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of Middle East and Africa)
Get more information on this report: Request Free Sample PDF

Browse Key Market Insights with Data Illustration:


Author Credits:  Radhika Pawar


  • Report ID: 486
  • Published Date: Oct 10, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2025, the industry size of muscle relaxant drugs is estimated at USD 3.62 million.

The muscle relaxant drugs market size was valued at USD 3.43 million in 2024 and is poised to cross USD 8.06 million by the end of 2037, registering more than 6.9% CAGR during the forecast period i.e., between 2025-2037. Upsurge in the use of muscle relaxants with other anaesthetics during surgical procedures, increasing sedentary lifestyle and decreasing levels of activity will boost the market growth.

North America is likely to dominate majority industry share by 2037, driven by upsurge in healthcare expenditure, low physical activity along with the high prevalence of musculoskeletal conditions affecting people of all ages in the region.

The major players in the market include AbbVie Inc., Antisense Therapeutics Limited, Sandoz International GmbH, Abbott Laboratories, Pfizer, Inc., Merck & Co., Inc., SteriMax Inc., Vertical Pharmaceuticals, LLC, Instas Pharmaceuticals Ltd., F. Hoffmann-La Roche Ltd.
Inquiry Before Buying Request Free Sample
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample